ArticleEuropean radiology2026
Visualization quality and effectiveness of noncontrast-abbreviated magnetic resonance imaging for hepatocellular carcinoma surveillance in cirrhotic patients with ultrasound visualization score C.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThe recently updated Liver Imaging Reporting and Data System version 2024 Surveillance US algorithm introduced alternative strategies, including abbreviated MRI, for patients with repeat or at high risk for repeat US visualization score C (VIS-C) examinations. This study aimed to evaluate the liver visualization quality and the effectiveness of noncontrast-abbreviated MRI (NC-AMRI) for hepatocellular carcinoma (HCC) surveillance in cirrhotic patients with US VIS-C. MATERIALS AND
methodsThis retrospective study included Child-Pugh class A or B cirrhotic patients with prior US VIS-C and who underwent NC-AMRI for HCC surveillance between December 2018 and July 2022. Two radiologists independently assessed the visualization quality based on liver parenchymal heterogeneity, artifacts, and liver visualization range, and assigned visualization scores (VIS-A, no or minimal limitations; VIS-B, moderate limitations; and VIS-C, severe limitations) on diffusion-weighted image (DWI) and T2-weighted image (T2WI) of NC-AMRI. Early-stage HCC detection was determined.
resultsA total of 264 patients (mean age, 60.2 years; 169 men) were included. In NC-AMRI after US VIS-C, the visualization score on DWI was A in 60.6% (160/264), B in 31.1% (82/264), and C in 8.3% (22/264), and the visualization score on T2WI was A in 78.4% (207/264), B in 16.7% (44/264), and C in 4.9% (13/264). Of the 18 patients detected with HCCs in NC-AMRI, 17 patients (94.4%) had early-stage HCC.
conclusionNC-AMRI provided adequate visualization quality in more than 91% of cirrhotic patients with US VIS-C and demonstrated effectiveness for early-stage HCC detection. KEY POINTS: Question What are the liver visualization quality and the effectiveness of noncontrast-abbreviated MRI (NC-AMRI) for hepatocellular carcinoma (HCC) surveillance in cirrhotic patients with US visualization score C (VIS-C)? Findings After US VIS-C, NC-AMRI achieved VIS-A or B in 91.7% on DWI and 95.1% on T2WI; among 18 HCCs detected, 94.4% were early stage. Clinical relevance NC-AMRI may provide acceptable liver visualization (DWI 91.7%, T2WI 95.1%) in US VIS-C cirrhosis and may facilitate early-stage HCC detection (94.4% early); findings warrant confirmation in larger, prospective, multi-center cohorts.
Indexed as
Identifiers
42622887What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.